- Home
- YGMZ vs ALZN Comparison
YGMZ vs ALZN Comparison
Compare YGMZ & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- ALZN
- Stock Information
- Founded
- YGMZ 2002
- ALZN 2016
- Country
- YGMZ China
- ALZN United States
- Employees
- YGMZ N/A
- ALZN N/A
- Industry
- YGMZ Transportation Services
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- YGMZ Consumer Discretionary
- ALZN Health Care
- Exchange
- YGMZ Nasdaq
- ALZN Nasdaq
- Market Cap
- YGMZ 10.7M
- ALZN 9.0M
- IPO Year
- YGMZ 2020
- ALZN 2021
- Fundamental
- Price
- YGMZ $0.15
- ALZN $2.40
- Analyst Decision
- YGMZ
- ALZN Strong Buy
- Analyst Count
- YGMZ 0
- ALZN 1
- Target Price
- YGMZ N/A
- ALZN $42.00
- AVG Volume (30 Days)
- YGMZ 42.2M
- ALZN 104.9K
- Earning Date
- YGMZ 01-01-0001
- ALZN 12-11-2025
- Dividend Yield
- YGMZ N/A
- ALZN N/A
- EPS Growth
- YGMZ N/A
- ALZN N/A
- EPS
- YGMZ N/A
- ALZN N/A
- Revenue
- YGMZ $40,429,750.00
- ALZN N/A
- Revenue This Year
- YGMZ N/A
- ALZN N/A
- Revenue Next Year
- YGMZ N/A
- ALZN N/A
- P/E Ratio
- YGMZ N/A
- ALZN N/A
- Revenue Growth
- YGMZ N/A
- ALZN N/A
- 52 Week Low
- YGMZ $0.11
- ALZN $2.06
- 52 Week High
- YGMZ $1.54
- ALZN $14.31
- Technical
- Relative Strength Index (RSI)
- YGMZ 33.34
- ALZN 47.73
- Support Level
- YGMZ $0.12
- ALZN $2.43
- Resistance Level
- YGMZ $0.25
- ALZN $2.61
- Average True Range (ATR)
- YGMZ 0.02
- ALZN 0.17
- MACD
- YGMZ 0.00
- ALZN 0.01
- Stochastic Oscillator
- YGMZ 28.89
- ALZN 31.71
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.